1. Germany Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Eckert & Ziegler SE

Eckert & Ziegler SE

13.25
EUR
+0.40
(+3.11%)
0.80EPS
19.38P/E
963.68MMarket Cap
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.85
2.01
2.2
1.89
2.18
2.72
2.9
2.85
2.91
3.57
3.94
4.73
4.99
4.99
Basic EPS, GAAP
0.14
0.11
0.17
0.15
0.23
0.26
0.36
0.34
0.56
0.47
0.42
0.53
0.78
0.79
Free Cash Flow per Basic Share
0.08
0.04
0.2
0.23
0.36
0.24
0.54
0.45
0.08
0.12
0.34
0.79
0.52
0.38
Dividend per Share
0.05
0.05
0.05
0.05
0.05
0.07
0.1
0.14
0.15
0.17
0.17
0.02
0.17
- -
Book Value per Share
1.32
1.4
1.57
1.66
1.77
2.02
2.22
2.35
3.01
3.4
3.56
3.57
4.02
4.3
Tangible Book Value per Share
0.49
0.52
0.72
0.82
0.96
1.15
1.4
1.72
2.02
1.84
2.78
2.78
3.29
3.55
Basic Weighted Avg Shares
63
63
63
63
63
62
62
62
62
62
62
63
63
63
Sales/Revenue/Turnover
117
127
140
120
139
169
178
176
180
222
246
296
312
313
Operating Margin (%)
10.98
9.65
12.67
12.84
12.54
12.85
19.29
19.93
18.97
20.66
18.93
22.72
24.13
23.81
Depreciation Expense
9
7
9
9
9
9
11
11
10
11
13
19
17
17
Net Income, GAAP
9
7
11
10
15
16
22
21
35
29
26
33
49
50
Effective Tax Rate (%)
14.86
44.92
33.21
32.24
30.68
26.2
28.06
30.93
25.29
30.72
27.95
29.97
32.34
31.34
Profit Margin (%)
7.71
5.32
7.67
7.97
10.6
9.56
12.34
12.09
19.14
13.17
10.69
11.25
15.63
15.91
Working Capital
41
35
49
60
82
88
103
124
117
118
150
153
176
178
LT Debt
18
7
5
4
- -
- -
17
18
17
47
47
46
35
31
Total Equity
90
94
105
110
118
124
138
146
193
214
224
225
253
271
Return on Invested Capital (%)
10.14
5.94
9.99
8.4
10.71
13.52
15.63
14.49
17.23
13.22
12.32
15.05
17.43
16.79
Return on Capital (%)
8.02
7.03
10.31
8.35
12.36
13.06
15.84
13.47
18.27
12.45
10.56
12.5
17.74
17.95
Return on Common Equity (%)
11
7.87
11.39
9.32
13.52
13.73
16.96
15.08
20.76
14.66
12.11
14.93
20.52
20.14

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
10
10
10
LT Borrowings
7
6
4
LT Finance Leases
28
28
27
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
63
63
63
Market Capitalization
954
900
964

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
248
255
250
Cash, Cash Equivalents & STI
129
124
110
Accounts Receivable, Net
45
52
49
Inventories
46
48
49
Total Current Liabilities
72
75
72
Payables & Accruals
- -
- -
- -
ST Debt
10
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.52%
12.09%
12.53%
Free Cash Flow
39.83%
50.87%
-34.41%
Net Income, GAAP
19.58%
21.98%
46.54%
Sales/Revenue/Turnover
8.96%
12.4%
5.45%
Total Cash Common Dividend
- -
165.78%
900.77%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
68
78
70
80
296
2025
68
81
75
88
312
2026
73
76
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.15
0.09
0.16
0.53
2025
0.16
0.19
0.14
0.3
0.78
2026
0.17
0.19
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.02
2025
- -
- -
- -
- -
0.17
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Harald Hasselmann
Full Time Employees
1,116
Sector
Health technology
Industry
Medical specialties
Address
Robert-Rössle-Straße 10 Berlin Germany 13125
IPO Date
May 25, 1999
Website
ezag.de
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Eckert & Ziegler SE Eckert & Ziegler SE is a Germany-based provider of isotope technology for medical, scientific, and industrial applications, with headquarters in Berlin and operations spanning Europe, North America, Asia-Pacific, and other regions. Founded in 1997 as a holding company, the group traces its roots to 1992 through predecessor entities like BEBIG GmbH and operates through two primary segments: Medical, which offers radiopharmaceuticals, radiochemicals, and contract manufacturing services for cancer diagnostics and therapy including brachytherapy solutions and radionuclide production such as lutetium-177 and actinium-225; and Isotope Products, which manufactures and distributes radiation sources, standards, and components for industrial radiometry, nuclear imaging, material testing, and scientific research. The company serves healthcare providers, pharmaceutical firms, research institutions, and industrial clients globally, with over 1,000 employees supporting production, development, and distribution from facilities including subsidiaries like Eckert & Ziegler Isotope Products in California and Eckert & Ziegler Radiopharma GmbH in Berlin. Recent developments include a November 2024 technology collaboration and license agreement with Telix Pharmaceuticals for cyclotron-based actinium-225 production to advance targeted alpha therapies; a March 2025 global supply agreement with AtomVie Global Radiopharma for non-carrier-added lutetium-177 chloride to bolster CDMO activities; an April 2024 partnership with RLS Radiopharmacies to expand gallium-68 radiopharmaceutical production; divestment of the HDR tumor irradiation division; acquisition of majority stake in PentixaPharm for drug development followed by its spin-off; and a change of legal form to Societas Europaea (SE).